for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quidel Corporation

QDEL.O

Latest Trade

117.20USD

Change

-1.01(-0.85%)

Volume

235,328

Today's Range

116.71

 - 

120.70

52 Week Range

104.40

 - 

306.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
118.21
Open
117.75
Volume
235,328
3M AVG Volume
20.54
Today's High
120.70
Today's Low
116.71
52 Week High
306.72
52 Week Low
104.40
Shares Out (MIL)
42.55
Market Cap (MIL)
5,029.93
Forward P/E
6.01
Dividend (Yield %)
--

Next Event

Quidel Corp Annual Shareholders Meeting

Latest Developments

More

Quidel Reports First Quarter 2021 Financial Results

Quidel Sees Q1 Revenue $374 mln to $376 mln

Quidel’S Sofia® SARS Antigen Test Receives Emergency Use Authorization For Screening Use With Serial Testing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quidel Corporation

Quidel Corp. is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassays, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of many diseases and medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Amplivue, Lyra and Thyretain.

Industry

Biotechnology & Drugs

Contact Info

9975 Summers Ridge Road

SAN DIEGO, CA

92121

United States

+1.858.5521100

http://www.quidel.com/

Executive Leadership

Kenneth F. Buechler

Independent Chairman of the Board

Douglas C. Bryant

President, Chief Executive Officer, Director

Randall J. Steward

Chief Financial Officer

Robert Joseph Bujarski

Chief Operating Officer

Michael Donald Abney

Senior Vice President - Distribution

Key Stats

2.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.5K

2019

0.5K

2020

1.7K

2021(E)

1.7K
EPS (USD)

2018

3.040

2019

2.970

2020

19.920

2021(E)

19.674
Price To Earnings (TTM)
5.44
Price To Sales (TTM)
2.70
Price To Book (MRQ)
3.38
Price To Cash Flow (TTM)
5.04
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
74.04
Return on Equity (TTM)
61.89

Latest News

Latest News

Qiagen is interested in organic growth and acquisitions - CEO

Genetic testing specialist Qiagen's Chief Executive Thierry Bernard said the company is interested in organic growth and "bolt-on" acquisitions, when asked about recent merger and acquisition speculation during a results conference call on Wednesday.

Nevada's prohibition of Quidel, Becton Dickinson's COVID-19 tests violates law: HHS official

U.S. state of Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's (BD) Veritor point of care antigen tests in long-term care facilities violates federal law, a U.S. government official said on Friday.

BRIEF-Quidel Sees Q2 2020 Revenue Of $201 Million To $202 Million

* QUIDEL ANNOUNCES PRELIMINARY REVENUE FOR SECOND QUARTER 2020

BRIEF-Quidel Receives Barda Funding To Develop Point-Of-Care Diagnostic Assay That Includes COVID-19

* QUIDEL RECEIVES BARDA FUNDING TO DEVELOP POINT-OF-CARE DIAGNOSTIC ASSAY THAT INCLUDES COVID-19

BRIEF-Quidel Receives Amended Emergency Authorization For Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument

* QUIDEL RECEIVES AMENDED EMERGENCY AUTHORIZATION FOR RAPID ANTIGEN COVID-19 DIAGNOSTIC ASSAY USING SOFIA 1 INSTRUMENT

BRIEF-Quidel's LyraDirect SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step

* QUIDEL’S LYRA® DIRECT SARS-COV-2 ASSAY RECEIVES EMERGENCY USE AUTHORIZATION AND CE MARK FOR MOLECULAR DETECTION OF COVID-19, WITHOUT EXTRACTION STEP Source text for Eikon: Further company coverage:

FDA grants emergency use authorization to Quidel for first antigen test for COVID-19

The U.S. Food and Drug Administration (FDA) on Saturday approved emergency use authorization (EUA) to Quidel Corp <QDEL.O> for the first COVID-19 antigen test.

U.S. FDA grants emergency use authorization to Quidel for first antigen test for COVID-19

The U.S. Food and Drug Administration (FDA) on Saturday approved emergency use authorization (EUA) to Quidel Corp for the first COVID-19 antigen test.

BRIEF-Quidel Receives Emergency Authorization For Rapid Antigen Covid-19 Diagnostic Assay

* QUIDEL RECEIVES EMERGENCY AUTHORIZATION FOR RAPID ANTIGEN COVID-19 DIAGNOSTIC ASSAY

BRIEF-Quidel Reports First Quarter 2020 Financial Results

* Q1 REVENUE $174.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $160.7 MILLION

BRIEF-Quidel's Lyra Direct Sars-Cov-2 Assay Submitted For Emergency Use Authorization For Molecular Detection Of Covid-19, Without Extraction Step

* QUIDEL’S LYRA® DIRECT SARS-COV-2 ASSAY SUBMITTED FOR EMERGENCY USE AUTHORIZATION FOR MOLECULAR DETECTION OF COVID-19, WITHOUT EXTRACTION STEP Source text for Eikon: Further company coverage:

BRIEF-Quidel Corp Says Lyra Sars-Cov-2 Assay Has Received Expanded Emergency Use Authorization Claims From FDA

* LYRA SARS-COV-2 ASSAY HAS RECEIVED EXPANDED EMERGENCY USE AUTHORIZATION (EUA) CLAIMS FROM FOOD AND DRUG ADMINISTRATION

BRIEF-Quidel Receives Emergency Use Authorization For Molecular Covid-19 Diagnostic Assay

* QUIDEL RECEIVES EMERGENCY USE AUTHORIZATION FOR MOLECULAR COVID-19 DIAGNOSTIC ASSAY

BRIEF-Quidel Reports Fourth Quarter And Full Year 2019 Financial Results

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Quidel Reports Q1 Non-GAAP Earnings Per Share $1.29

* Q1 REVENUE $169.1 MILLION VERSUS I/B/E/S VIEW $150.9 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up